| scholarly article | Q13442814 |
| P2093 | author name string | Qian Cheng | |
| Yang Wang | |||
| Siqi Wang | |||
| Zhao Li | |||
| Xiao Xiang | |||
| Jiye Zhu | |||
| Changkun Zhang | |||
| Shihua Hu | |||
| Xiaodong Xun | |||
| P2860 | cites work | Modeling Development and Disease with Organoids | Q24657457 |
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Toward understanding and exploiting tumor heterogeneity | Q28603034 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| Organoid cultures derived from patients with advanced prostate cancer | Q34545103 | ||
| A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer | Q35237480 | ||
| HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity | Q35757997 | ||
| Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells | Q36997036 | ||
| Cancer stem cells: implications for the progression and treatment of metastatic disease. | Q37053174 | ||
| Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 | ||
| Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models | Q37565162 | ||
| Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents | Q37714306 | ||
| Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways | Q37820099 | ||
| Control of stem cells and cancer stem cells by Hedgehog signaling: pharmacologic clues from pathway dissection | Q38059538 | ||
| Targeting cancer stem cells to suppress acquired chemotherapy resistance | Q38149736 | ||
| Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. | Q38713045 | ||
| Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma | Q38812372 | ||
| High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. | Q38826826 | ||
| Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells. | Q38899847 | ||
| ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors | Q38947384 | ||
| Implication of the Hedgehog pathway in hepatocellular carcinoma. | Q39433923 | ||
| Hepatitis B virus X protein stimulates the Hedgehog-Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells | Q39512904 | ||
| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 | ||
| Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. | Q43996886 | ||
| Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis | Q46843790 | ||
| Human primary liver cancer-derived organoid cultures for disease modeling and drug screening | Q48317424 | ||
| A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. | Q48574942 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| MEKK2 and MEKK3 suppress Hedgehog pathway-dependent medulloblastoma by inhibiting GLI1 function. | Q52584558 | ||
| Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. | Q52602391 | ||
| Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression. | Q52668585 | ||
| The biology and role of CD44 in cancer progression: therapeutic implications. | Q54110894 | ||
| Activation of the hedgehog pathway in human hepatocellular carcinomas. | Q54616323 | ||
| Hepatocellular carcinoma | Q58020832 | ||
| Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies | Q58450461 | ||
| Intra-tumour diversification in colorectal cancer at the single-cell level | Q59064996 | ||
| The molecular connection of histopathological heterogeneity in hepatocellular carcinoma: A role of Wnt and Hedgehog signaling pathways | Q60047391 | ||
| CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line | Q64262837 | ||
| Cancer modeling meets human organoid technology | Q69497099 | ||
| Stem cell fate in cancer growth, progression and therapy resistance | Q91518791 | ||
| Silencing of the MEKK2/MEKK3 Pathway Protects against Spinal Cord Injury via the Hedgehog Pathway and the JNK Pathway | Q92419809 | ||
| Hepatocellular Carcinoma | Q93002915 | ||
| P433 | issue | 1 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| organoid | Q11293125 | ||
| P304 | page(s) | 22 | |
| P577 | publication date | 2020-01-28 | |
| P1433 | published in | Journal of Experimental & Clinical Cancer Research | Q13739415 |
| P1476 | title | Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids | |
| P478 | volume | 39 |
Search more.